**Summary**
Dr. Martens PLCs preliminary results for FY26 show a 61% increase in adjusted profit before tax (PBT), reaching ยฃ55.0 million, despite a slight revenue decline of 2.9% to ยฃ764.9 million. The company attributes this growth to a shift from a channel-led to a consumer-first operating model, with a focus on improving revenue quality and strengthening margins. Shoes were the standout category, with a 19% revenue increase. The company also made progress in its strategic pivot, reducing reliance on discounted pairs in the USA wholesale market by 31% and growing product families like Lowell, Buzz, and Zebzag.
In FY26, Dr. Martens achieved its strategic objectives, including reducing discounted pairs in the USA, growing product families, expanding into new markets, and simplifying its operating model. The company reorganized its business in Q4, removing the regional structure and adopting a market model for FY27, led by a streamlined Executive Team.
Looking ahead to FY27, Dr. Martens plans to enter the scale phase of its strategy, focusing on higher-quality revenues and operational leverage. The company will increase brand investment, upgrade retail stores, and strengthen wholesale partnerships to support demand. Despite navigating an unpredictable trading environment, Dr. Martens remains confident in its medium-term targets, underpinned by its improved revenue quality, strong wholesale order books, and enhanced operational resilience.